Celltrion spends $450m to ramp up contract drug production

South Korean pharma maker seeks to tap booming overseas demand

20201119N Celltrion

Celltrion's headquarters in Incheon, South Korea. © Reuters

KOTARO HOSOKAWA, Nikkei staff writer

SEOUL -- Major South Korean drugmaker Celltrion will invest 500 billion won ($448 million) to build a factory and an R&D center at its complex in Incheon, adding 60,000 liters to its total annual capacity to meet rising demand for contract manufacturing.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.